Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hyaluronidase PB3000 is a recombinant enzyme developed by Proteos Biotech, specifically formulated at a concentration of 3000 IU. Derived from *Streptococcus pyogenes*, this biologic agent functions by enzymatically degrading hyaluronic acid (HA) within the extracellular matrix. It is primarily indicated for the management of complications associated with hyaluronic acid-based dermal fillers, such as overcorrection, improper placement, or inflammatory reactions. Additionally, it is utilized in aesthetic medicine for facial, periocular, and hand rejuvenation, as well as for treating cellulite and localized fibrosis. The enzyme promotes tissue drainage and the resorption of excess fluids and hyaluronic acid accumulations. It is administered via intradermal or subcutaneous injection by healthcare professionals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hyaluronidase PB3000.